Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

Published:2016-11-21 Issue:2 Volume:35 Page:198-206
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Paz-Ares Luis,Forster Martin,Boni Valentina,Szyldergemajn Sergio,Corral Jesús,Turnbull Samantha,Cubillo Antonio,Teruel Carlos Fernandez,Calderero Iker López,Siguero Mariano,Bohan Patrick,Calvo Emiliano

Funder

Pharma Mar, S.A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-016-0410-3.pdf

Reference28 articles.

1. Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 161(5):1099–1110

2. Bueren-Calabuig JA, Giraudon C, Galmarini CM, Egly JM, Gago F (2011) Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res 39(18):8248–8257. doi: 10.1093/nar/gkr512

3. Santamaria G, Martínez-Leal JF, Cuevas C, Garcia-Fernandez LF, Galmarini CM Lurbinectedin (PM01183) specifically targets RNA Pol II for degradation via the proteasome pathway in a transcription and TC-NER dependent fashion. Eur J Cancer 50:20. doi: 10.1016/S0959-8049(14)70173-x